EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C



Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C



Arquivos de Gastroenterologia 41(2): 132-133



Aim - Report of a case of a woman patient who developed celiac disease after pegylated interferon alpha-2a and ribavirin use for chronic hepatitis C. Patient and Method - A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and ribavirin for 6 months, developed progressive malaise and anemia 6 months after the end of treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 011836342

Download citation: RISBibTeXText

PMID: 15543388

DOI: /S0004-28032004000200012



Related references

Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin. Bratislavske Lekarske Listy 112(6): 360-362, 2011

Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study. Hepato-Gastroenterology 54(75): 2 P Preceding Table of Contents-2 P Preceding Table of Contents, 2007

A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C. Internal Medicine 49(18): 1987-1990, 2011

Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Research and Clinical Practice 86(2): E19-E21, 2010

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology 53(3): 146-153, 2010

Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment. Gut and Liver 1(1): 87-89, 2007

New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. Israel Medical Association Journal 11(12): 760-761, 2010

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Journal of Medical Virology 82(12): 2027-2031, 2011

Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C. Journal of Gastroenterology and Hepatology 21(3): 622-623, 2006

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Journal of Gastroenterology and Hepatology 23(6): 861-866, 2008

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Journal of Antimicrobial ChemoTherapy 63(6): 1256-1263, 2009

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology & Therapeutics 24(7): 1079-1086, 2006

Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients. Virology Journal 8(): 234-234, 2011